(BofA) – Seer Publicizes Pricing of Preliminary Public Providing
Information and analysis earlier than you hear about it on CNBC and others. Declare your 1-week free trial to StreetInsider Premium right here.
REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) — Seer, Inc., a life sciences firm targeted on enabling distinctive scientific outcomes via the ability of unbiased, deep, fast and scalable proteomics data, at this time introduced the pricing of its preliminary public providing of 9,210,527 shares of Class A standard stock at a public providing price of $19.00 per share. All the shares of Class A standard stock are being provided by Seer. The gross proceeds from the providing, earlier than deducting underwriting reductions and commissions and different providing bills payable by Seer, are anticipated to be $175 million, excluding any train of the underwriters’ choice to buy extra shares. Seer’s Class A standard stock is predicted to start buying and selling on the Nasdaq World Choose Market on December 4, 2020, underneath the ticker image “SEER.” The providing is predicted to shut on December 8, 2020, topic to the satisfaction of customary closing situations. As well as, Seer has granted the underwriters a 30-day choice to buy as much as a further 1,381,579 shares of Class A standard stock on the preliminary public providing price, much less the underwriting reductions and commissions.
J.P. Morgan, Morgan Stanley, (BofA) Securities and Cowen are appearing as lead book-running managers for the providing.
Registration statements referring to the shares being bought on this providing was declared efficient by the Securities and Alternate Fee on December 3, 2020. The providing is being made solely via a prospectus, copies of which may be obtained, when accessible, from: J.P. Morgan Securities LLC, c/o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, New York 11717, by way of phone: +1 (866) 803-9204, or by emailing email@example.com; Morgan Stanley & Co. LLC, Consideration: Prospectus Division, 180 Varick Street, 2nd Flooring, New York, NY 10014; (BofA) Securities, NC1-004-03-43, 200 North Faculty Street, third Flooring, Charlotte, NC 28255-0001, Consideration: Prospectus Division, or by e-mail at firstname.lastname@example.org; and Cowen and Firm, LLC, c/o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, NY 11717, by way of phone: +1 (833) 297-2926, or by emailing PostSaleManualRequests@broadridge.com. Copies of the ultimate prospectus, when accessible, associated to the providing can be accessible at www.sec.gov.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction during which such provide, solicitation or sale could be illegal previous to the registration or qualification underneath the securities legal guidelines of any such state or different jurisdiction.
About Seer Seer is a life sciences firm targeted on enabling distinctive scientific outcomes by commercializing transformative merchandise that can drive breakthrough concepts by unlocking the deep, unbiased organic data that may make them a actuality. Seer is creating its Proteograph™, which is an built-in resolution consisting of consumables, automation instrumentation and proprietary software program that performs deep, unbiased proteomics evaluation at scale in a matter of hours. Seer designed the Proteograph to be environment friendly and easy-to-use, leveraging broadly adopted laboratory instrumentation to offer a decentralized resolution broadly accessible to life sciences researchers.
Investor ContactCarrie Mendivilinvestor@seer.bio
Supply: Seer, Inc.